Qing Chen,Shaojin Zhu,Nanlin Jiao,Ziyu Zhang,Guangjian Gao,Wenqiang Zheng,Gang Feng,Wenzheng Han
The early diagnosis of lung cancer is closely associated with the decline of mortality. A panel consisting of seven lung cancer‑related autoantibodies (7‑AABs) has been shown to be a reliable and specific indicator for the early detection of lung cancer, with a specificity of ~90% and a positive predictive value of ~85%. However, its low sensitivity and negative predictive value limit its wide application. To improve its diagnostic value, the diagnostic efficiencies of 7‑AABs in combination with non‑specific tumor markers were retrospectively investigated for the detection of early‑stage lung cancer. A total of 217 patients with small lung nodules who presented with ground‑glass opacity or solid nodules as well as 30 healthy controls were studied. The concentrations of 7‑AABs and heat shock protein 90a (HSP90a) were assessed using ELISA. Automated flow fluorescence immune analysis was used for the assessment of CEA, CYFRA21‑1, CA199 and CA125 levels. The results showed that 7‑AABs + HSP90a possessed a remarkably improved diagnostic efficiency for patients with small pulmonary nodules or for patients with lung nodules of different types, which suggested that 7‑AABs in combination with HSP90a could have a high clinical value for the improvement of the diagnostic efficiency of early‑stage lung cancer.
Circulating Tumor Cells (CTCs) enrichment technology refers to medical approaches for capturing and isolating target tumor cells, which has drawn great attention owing to its applications in the clinic such as cancer diagnosis and prognosis. Magnetic nanoparticles have emerged as an important platform for CTCs capture and isolation. However, due to the inert surface nature, the molecular phenotype analysis of CTCs and identification sensitivity remain a huge challenge. Herein, an ultrasound-activated microfluidic method is presented for rapid basic modification of magnetic nanoparticles, laying the foundation for further covalently binding of functional groups to capture CTCs. In this work, Fe 3 O 4 @SiO 2 nanoparticles obtained from microfluidics are hybrid with folic acid for the capture and isolation of CTCs with folate receptors such as Hela cells. The usage of microfluidic technology to upgrade Fe 3 O 4 nanoparticles provides the possibility for improving the detective efficiency of rare cells associated with malignancies, which sheds new light on future clinical applications.
危险品化学品经营许可证（带存储）